Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice by Chio, C-C et al.
Fas/Fas-L signalling system plays an important role in immune
homeostasis (Nagata, 1997). Fas-L (also termed as CD95L, APO-
1L) is a member of the tumour necrosis factor receptor super-
family and may trigger a death signal into Fas-bearing cells after
engagement with Fas molecule (Itoh et al, 1991; Takahashi et al,
1994). Contrast to a well-regulated manner in lymphocytes
(Alderson et al, 1995; Van Parijs and Abbas, 1996), Fas-L is
constitutively expressed in several non-lymphoid tissues as well as
in tumours of various origins. The expression of functional Fas-L
on some tumour cells may confer them the ability to kill T cells in
vitro (Hahne et al, 1996; Strand et al, 1996; Walker et al, 1998).
These findings led to an assumption that Fas-L might contribute to
immune privilege of tumours. However, using Fas-L-positive cells
for organ transplantation or ectopic expression of Fas-L in trans-
genic animals revealed that Fas-L could also enhance immune
destruction of Fas-L-positive cells (Chervonsky et al, 1997; Seino
et al, 1997). Under certain growth conditions, cross-linking of Fas
transmits signal for proliferation instead of death signal in tumours
as well as in immune cells (Alderson et al, 1993, Owen-Schaub
et al, 1994). More complicatedly, a reverse signalling of Fas-L has
been reported in cytotoxic lymphocytes, where Fas-L augmented
cell proliferation following its ligation (Suzuki and Fink, 1998). 
Glioma cells express Fas-L and induce apoptosis in Fas-
expressing cell lines ex vivo (Gratas et al, 1997; Saas et al, 1997;
Yang et al, 2000). While, glioma cells can also express Fas and are
susceptible to Fas-L-triggered death indicating that a subtle
balance of growth and death signals exists in vivo (Weller et al,
1994; Yang et al, 1999). Conversely, endogenous Fas/Fas-L inter-
action in glioma cells could provide signal driving cell cycle
progression in glioma cells probably through the MEK-ERK
pathway (Shinohara et al, 2000). In this study, we constructed a
Fas-L-specific hammerhead ribozyme (Fas-Lribozyme), placed
upstream of enhanced green fluorescent protein (EGFP) gene to
suppress the Fas-L expression in human glioma cells. Ribozyme
catalyses endoribonucleolytic cleavage of substrate RNA in trans
with a sequence-specific manner (Birikh et al, 1997; Poeschla and
Wong-Staal, 1997) and has been exploited to inhibit genes such as
fos, ras and fas-L (Scanlon et al, 1991; Du et al, 1996; Chang et al,
1997). Our Fas-Lribozyme recognizes the Fas-L transcript at site
coding for the extracellular domain of Fas-L. After transfection
into glioma cells, Fas-Lribozyme inhibited the expression of Fas-L at
both mRNA and protein levels. Stable transfectants of glioma cells
carrying Fas-Lribozyme were established to explore the role of Fas-L
on cell growth, apoptosis, and tumour formation in nude mice.
Here, we present evidence that down-regulation of endogenous
Fas-L in tumour cells not only affects viability of tumour cells but
also reduces local immune responses that may consequently
modify tumour formation. 
MATERIALS AND METHODS 
Cells and cell culture condition 
Human glioma cell lines U-373MG and U-118MG were purchased
from the American Type Culture Collection (Rockville, MD).
Transfectants carrying plasmid pEGFP-N1 (vector controls) or
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Dulbecco modified Eagles’ medium (DMEM; Life Technologies,
Grand Island, NY) supplemented with 20% fetal calf serum (FCS),
1% penicillin and 1% fungizone at 5%CO2 /37˚C in a humidified
atmosphere. Growth rate was measured by counting viable cell,
which was determined by trypan blue exclusion. MTT assay was
applied to estimate cellular viability using a commercially avail-
able kit (CellTiter 96® Aqueous, Promega, Madison, WI). In brief,
cells were seeded in 96-well plates (5 × 104 cells well–1), grew for
72 h to confluence, and the WST-8 (2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolumn) was
added the last 2 h before the end of culture. The cell-bound dye
was measured by optical absorption at 490 nm using a microplate
reader. 
Construction of Fas-Lribozyme
The sequences of the oligonucleotides used to construct 
Fas-Lribozyme were as follow: sense sequence: 5′-
ATG/AAT/TCC/CGG/AAG/TAC/TGA/TGA/GTC/GTC/ATA/
CGA/ CGA/AAC/TTT/GGA/ TCC/CGA-3′; antisense sequence: 5′-
TCG/GGA/TCC/AAA/GTT/TCG/CG/TAT/CAC/GAC/TCA/TCA/
GTA/CTT/CCG/GGA/ATT /CAT-3′. This sequence is corresponding
to the coding region in the extracellular domain of Fas-L and does
not share homology to other genes according to database search on
GenBank, EMBL, PDB and DDBJ. After annealing of these oligonu-
cleotide pairs, the generated fragment was digested with EcoR1 and
BamH1, followed by ligation into the EcoR1/BamH1-predigested
vector plasmid pEGFP-N1 (Clontech, palo Atto, CA). In this plasmid
construct, the ribozyme was directly linked to upstream of the EGFP
gene to form a fusion transcript (Figure 1), so that the Fas-Lribozyme can
be monitored indirectly by the expression of EGFP protein.
Candidate clone was verified by DNA sequencing. 
DNA transfection 
Plasmid DNA was delivered into cells using the lipofection
method with a ratio of 1 µg DNA /20 µl lipofectamine (Qiagen,
Hilden, Germany). Plasmid pEGFP-N1 served as the non-
ribozyme control. After DNA transfection, cells were grown
in regular 20% FCS/DMEM for 48 h, and then selected
with geneticin (G418, Sigma, St Louis, MO) at an effective
concentration of 0.5 µg ml–1 for at least 3 months before
subjected to further study. Stable transfectants derived from U-
373MG and U 118MG carrying either Fas-Lribozyme or pEGFP-N1
plasmid were designated as Fas-Lribozyme (U-373MG), Fas-
Lribozyme (U-118MG), EGFP(U-373MG) and EGFP(U-118MG),
respectively. 
Semi-quantitative reversed transcription-polymerase
chain reaction (RT-PCR) 
Total RNA was purified using the RNeasy Kit followed the manu-
facturer’s instruction (Qiagen) and converted to cDNA by
StrataScrip™-H-reverse transcriptase with oligo-dT primer in the
presence of RNAsin (Stratagen, La Jolla, CA). RT-PCR for Fas-L,
Fas, Bcl-2, FAP-1 and β-actin were performed as described previ-
ously (Cleary et al, 1986; Sato et al; 1995; Yang et al, 1998). The
generated cDNA was subjected to 35–40 cycles of PCR amplifica-
tion on a DNA thermal Cycler (Hybaid Omnigene, Middlesex,
UK). The existence of ribozyme in stable cells was verified by
RT-PCR with primer pair as follow: 5′-TCC/GCT/AGC/GCT/
ACC/GGA/CT- 3′ and 5′-GTC/CTT/GAA /GAA/GAT/GGT-3′.
This primer pair amplifies a 411 bp from the EGFP/Fas-Lribozyme
chimeric transcript spanning upstream of ribozyme into EGFP
gene, and a 400 bp DNA fragment from the transcript of authentic
EGFP gene. β-Actin served as a quantitative control in PCR. PCR
products were fractionated by agarose or NuSieve 3:1 agarose,
stained with ethidium bromide, and visualized under UV light. 
Western blot 
Cells were extracted with a buffer containing 20 mM Tris,
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM PMSF and
0.1 U ml–1 leupeptin. Proteins were separated in SDS-polyacryl-
amide gel and electroblotted onto polyvinyl difluoride membrane
(MSI, Westboro, MO). The proteins bounded on the membrane
were probed with mouse antibody (Ab)-recognizing Fas-L
(clone33; Transduction Laboratories, Lexington, KY) followed by
a sheep anti-mouse IgG conjugated with horseradish peroxidase
(Dako Corp, Carpinteria, CA). The Fas-L was made visible by
fluorography with enhanced chemiluminescence detection kit
(Amersham/Pharmacia Biotech, UK). Duplicate blot was probed
with α-tubulin-specific Ab (clone DMIA; NeoMarker, Fremont,
CA) and served as a protein-loading control. 
Detection of apoptotic cells 
Apoptotic cells in 3-day-old culture were stained with merocya-
nine 540 (MC540, Sigma) according to the published procedures
(Reid et al, 1996; Yang et al, 1999). Apoptotic cells became
susceptible to MC540 binding due to alteration of surface
membrane and showed FL2 values more than 230 detected by
flow cytometry analysis. Apoptotic cells in tumour nodules or
liver tissues were detected by TUNEL labelling detecting free 3′-
OH groups in fragmented DNA in situ (Apop Tag-peroxidase in
situ apoptosis detection kit, Oncor, MD). Paraffin-embedded,
slide-mounted tissue sections were deparaffinized, and treated
with proteinase K for 15 min followed by 3% H2O2 for 5 min.
After nick end labelling with digoxigenin-deoxyuridine triphos-
phate by deoxynucleotidyl transferase, immunostaining was
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Figure 1 Construction of Fas-Lribozyme. (A) Secondary structure of ribozyme
that cleaves the Fas-L mRNA at the coding region in the extracellular domain
of Fas-L. Arrow indicates the cleavage site. This Fas-Lribozyme is fused
upstream with EGFP gene. (B) Plasmid EGFP/Fas-Lribozyme was constructed
by ligation of the oligos encoding ribozyme sequence into EcoR1, BamH1-
digested pEGFP-N1. Arrows indicate the positions of primer set detecting the
chimaeric transcript (Fas-Lribozyme/EGFP) in PCR reactions performed using peroxidase-conjugated antidigoxigenin Ab for
30 min. Apoptotic cells were visualized with diaminobenzidine
substrate and became a dark brown colour. Specimen was counter-
stained with 0.3% methyl green or haematoxylin/eosin. 
Tumour formation in nude mice 
Male BALB/c-nu mice were purchased from the National
Laboratory Animal Breeding and Research Center, Taiwan, ROC
and maintained under specific pathogen-free condition. Mice at 8
weeks old were randomly divided into groups and 3–5 mice in a
group. Approximate 106 stable cells in 0.3 ml PBS were injected
subcutaneously into the upper flanks of each mouse. Tumour
formation was examined every other day. Injected cells were
considered as tumorigenic if tumour nodule with a size more than 3
mm developed at the injection site. Mice were sacrificed one week
after tumour nodules were formed. Tumour nodules and liver tissue
were surgically obtained, fixed in neutral-buffered formalin, pH
7.2, and then subjected to analyses on tumour-infiltrating cells and
apoptotic cells. Infiltrating macrophages and granulocytes were
morphologically identified based on the ratio of nuclear to cyto-
plasm and the presence or absence of granules. EGFP-expressing
cells in those tissues were immunostained using rabbit anti-EGFP
Ab (Clontech) followed by peroxidase-conjugated goat anti-rabbit
IgG Ab (Calbiochem, La Jolla, CA). Sections were counterstained
and mounted with glycerol gelatin before examination.
Statistical analysis 
Results were analysed by Student’s t-test. Differences with P < 0.05
were judged significant. 
RESULTS 
Fas-Lribozyme plasmid reduced the expression of Fas-L in
glioma cells 
After growing in geneticin-containing medium for 3 months, more
than 90% of stable transfectants carrying either Fas-Lribozyme or
pEGFP-N1 plasmid emitted green light under fluorescent
microscopy and were morphologically similar to the parental cells.
Bulk culture of DNA-transfected cells was used in this study to
avoid any bias deduced from cell lines having unwanted gene
backgrounds generated during selection. The chimeric transcripts
containing Fas-L-specific ribozyme and EGFP sequence were
detected in Fas-Lribozyme-carrying cells by RT-PCR as a 411 bp
DNA fragment (Figure 2A). A 400 bp PCR fragment was ampli-
fied from the cDNA of vector controls, which represents the
authentic transcript of the EGFP gene. Transfection of Fas-Lribozyme
did not affect the amount of Fas, Bcl-2 and FAP-1 transcripts in
both U-118MG and U-373MG cells (Figure 2B). A decrease in the
expression of Fas-L was observed in Fas-Lribozyme-carrying cells as
compared to those in vector controls at both mRNA (Figure 2B)
and protein (Figure 2C) levels. 
Fas-Lribozyme enhanced slightly the growth rate but
reduced spontaneous apoptosis of glioma cells in vitro 
Growth rate of stable transfectants was determined at 24, 48 and 72 h
after subculture in fresh medium (Figure 3). Fas-Lribozyme(U-373MG)
showed enhanced growth rate in vitro than EGFP(U-373MG). In
general, Fas-Lribozyme-carrying cells grew slightly faster than vector
controls, although elevation in growth rate in Fas-Lribozyme(U-
118MG) was not statistically significant. In addition, less floated
cells and apoptotic bodies appeared in 72-h culture of Fas-Lribozyme-
glioma cells than that of vector controls. The viability of the trans-
fectants in 72-h culture, in which cells grew to confluence, was
estimated by MTT assay (Figure 4). Fas-Lribozyme(U-373MG)
showed significantly better viability than EGFP(U-373MG). In
consistent with the growth rate, cellular viability of Fas-Lribozyme(U-
118MG) was not significant different from that of EGFP(U-
118MG). To further quantify the apoptosis, cells were stained 
with (MC540) (Figure 5). The proportion of MC540-positive cells
were 8.7% in culture of Fas-Lribozyme(U-373MG) as compared to
38.5% in culture of EGFP(U-373MG). Similarly, MC540-positive
cells in Fas-Lribozyme(U-118MG) were about 3-fold less than
Fas-Lribozyme alters tumorigenesis of human glioma 1187
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Figure 2 Decreased expression of Fas-L in Fas-ribozyme-carrying cells. After
transfection, cells were selected in geneticin-containing medium for 3
months. RNA was isolated and converted to cDNA as described in Materials
and Methods. (A) PCR-amplified products of chimeric Fas-Lribozyme (411 bp) in
Fas-Lribozyme(U-373MG) and Fas-Lribozyme(U-118MG) (lanes 1, 3), or EGFP
(400 bp) in EGFP(U-373MG) and EGFP(U-118MG) (lanes 2, 4). (B) PCR-
amplified products of Fas-L, Fas, Bcl-2, FAP-1 and β-actin. Lanes 1, 2, 3: U-
118MG, EGFP(U-118MG) and Fas-Lribozyme(U-118MG), respectively; lanes 4,
5, 6: U-373MG, EGFP(U-373MG) and Fas-Lribozyme(U-373MG), respectively.
(C) Western blot analysis. Lanes 1, 2: EGFP(U-373MG), Fas-Lribozyme(U-
373MG); lanes 3, 4: EGFP(U-118MG), Fas-Lribozyme(U-118MG), respectively.
α-Tubulin served as protein-loading control EGFP(U-118MG) (8.7% versus 22.2%). These results indicate
that as a result of Fas-L down-regulation, the Fas-Lribozyme transfec-
tants were more resistant to spontaneous cell death under
confluent growth condition. 
Tumour formation of EGFP/Fas-Lribozyme stable cells 
U-118MG produced tumours by 2–3 weeks after subcutaneous
inoculation into nude mice. Parental U-373MG cells were less
tumorigenic and produced tumours in mice around 8–9 weeks
after cell injection. To determine whether endogenous tumour Fas-
L involves in tumorigenesis, 106 cells, with or without Fas-Lribozyme,
were injected subcutaneously into the dorsal flanks of nude mice.
Results are summarized in Table 1. Fas-Lribozyme(U-118MG) and
EGFP(U-118MG) produced tumours in all animals by 2 weeks
post-injection with diameters of 3–5 mm and 2–4 mm, respec-
tively. EGFP(U-373MG), as expected, produced tumours of small
size (1.5–2 mm) and only 2 out of 3 mice developed tumours first
at 7.5 and 10 weeks post-injection. Interestingly, Fas-Lribozyme(U-
373MG) produced more tumours in all injected mice with diame-
ters of 3–4 mm about 3–5 weeks earlier. 
Histopathology 
Fas-Lribozyme altered the architecture of tumours. Tumour nodules of
Fas-Lribozyme-carrying cells showed loose margin and invasive charac-
ters (Figure 6). Immune cells showing morphology of mononuclear
cells/granulocytes accumulated in and around the tumour nodules
(Figure 7). There were less infiltrating cells in tumours produced
by Fas-Lribozyme carrying cells than those of vector controls (Table 2).
Notably, the infiltrating cells tended to accumulate near the margin
of tumour nodules produced by vector controls (Figure 7B).
Apoptotic cells showing fragmented nuclei and stained positive by
TUNEL staining (brown-coloured cells as shown in the represen-
tative pictures for U-373MG; Figure 8) were numerous in tumours
of EGFP(U-118MG) and EGFP(U-373MG). Apoptosis was signifi-
cantly reduced in tumour nodules of all Fas-Lribozyme-carrying cells as
compared to vector controls. 
Liver damage in tumour-bearing mice 
Multifocal, diffuse, necrotizing areas were frequently observed in
liver of mice bearing vector controls (Figure 9A, C), but less
in liver of mice bearing Fas-Lribozyme-carrying cells (Figure 9B).
Apoptotic cells showing morphological features of hepatocytes
were demonstrable in the liver lesion (Figure 9D). Take the advan-
tage that our established tumour cell lines express EGFP, the pres-
ence of tumour cells in situ was confirmed by histological
1188 C-C Chio et al 
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Figure 3 Growth curves of cells with or without Fas-Lribozyme. Cells were
grown in 20% FCS/DMEM at the initial density of 1 × 105 cells well–1 in a 6-
well plate. Cell number was counted every 24 h up to 72 h. Diamonds: cells
carrying Fas-Lribozyme; Squares: cells carrying EGFP-N1 plasmid. *:significant






































Figure 4 Cellular viability. About 5 × 104 cells were grown in 20%
FCS/DMEM for 72 h in a well of a 96-well plate. Cellular viability was
determined by MTT assay as described in Materials and Methods. Blank bar:
cells carrying EGFP-N1 plasmid served as controls; hatched bars: cells
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Figure 5 Apoptosis in 3-day culture of cells with or without Fas-Lribozyme.
Cells, with (solid lines) or without (filled gray curves) Fas-Lribozyme, were grown
in 20% FCS/DMEM for 72 h. Apoptotic cells were stained by MC540. Cells
with FL2>230 were judged as apoptotic 
Table 1 Summary of the effects of Fas-Lribozyme on tumour formation 
U-373MG U-118MG 
Control Fas-Lribozyme Control Fas-Lribozyme
Tumour size (mm3) 1.5–23 –42 –43 –5 
Tumour number (total in 
3 mice) 2 7 5 5 
Tumour formation (weeks) 7.5–10 4.5–52 2  
Infiltrating cells +++ + +++ + 
Apoptotic cells +++ ++ +++ + 
Liver damage ++ + +++ + 
Note: +++: severe; ++: moderate; +: mild; –/+: few; –: not found. immunostaining on EGFP protein (Figure 9E, F). Although all
EGFP-positive glioma cells, both Fas-Lribozyme-carrying cells and
vector controls, did not form gross detectable tumour nodules in
the liver by subcutaneous injection, a few EGFP-positive tumour
cells were found among the liver lesions and were morphologi-
cally different from those in subcutaneous tumour nodules
(comparing Figure 9E). 
DISCUSSION 
By using a hammerhead ribozyme we have successfully down-
regulated the expression of Fas-L in human glioma cells at both
mRNA and protein levels. Apoptosis in tumour cells was signifi-
cantly reduced by Fas-Lribozyme. In nude mice, Fas-Lribozyme-carrying
cells formed bigger tumours with significantly fewer infiltrating
cells in the tumour areas than vector controls. 
Fas/Fas-L signalling has been demonstrated to elicit apoptosis
in glioma cells in certain culture conditions (Weller et al, 1994;
Shinoura et al, 1998; Yang et al, 1999). Although cell cycle
progression in glioma cells could be promoted by activating Fas
antibody (CH-11) probably through the MEK-ERK pathway,
however, apoptosis occurred at the same time and the net viable
cell count was not increased (Shinohara et al, 2000). In addition,
transfer of Fas-L gene into Renca cells, a Fas signal-sensitive 
renal cell carcinoma caused a suicidal destruction of tumour 
cells by apoptosis (Arai et al, 1997). In consistence with those
findings, glioma cells carrying Fas-Lribozyme had reduced apoptosis
both in vitro and in vivo. Since Fas-Lribozyme did not alter the
expression of other death-related genes including Fas, Bcl-2, and
FAP-1, suppression of Fas-L gene by Fas-Lribozyme resulting in less
Fas/Fas-L ligation should account for the reduced apoptosis in
Fas-Lribozyme alters tumorigenesis of human glioma 1189
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Table 2 Tumour-infiltrating cells 
U-118MG U-373MG 
Ribozyme Vector Ribozyme Vector 
1/T ratioa 0.085 ± 0.059 0.162 ± 0.051* 0.041 ± 0.023 0.140 ± 0.058* 
G/T ratio 0.008 ± 0.004 0.053 ± 0.017* 0.002 ± 0.004 0.053 ± 0.036* 
M/T ration 0.037 ± 0.012 0.091 ± 0.049* 0.037 ± 0.021 0.082 ± 0.033* 
aI/T: infiltrating cells/total cells; G/T: granulocytes/total cells; M/T:
macrophages/total cells. Each value represents mean ± SD obtained from 3
mice of all groups except U-373MG/vector, the latter were obtained from 2
tumour-bearing mice. Infiltrating cells were randomly counted in 20 fields for
each mouse. *: Significant difference between ribozyme-carrying glioma cells




Figure 6 Tumour formation of U-118MG- and U-373MG-derived cells in nude mice. Approximate 106 stable cells, EGFP(A:U-118MG, C:U-373MG) or Fas-
Lribozyme(B:U-118MG, D:U-373MG), were injected subcutaneously into dorsal flanks of nude mice. Tumour tissues were formalin-fixed, paraffin-embedded, and
stained with haematoxylin/eosin those Fas-Lribozyme-carrying glioma cells. Down-regulation of Fas-
L by Fas-Lribozyme caused an increase in growth rate, improved cell
viability and speeded up tumour formation indicating that the
endogenous tumour Fas-L might not be growth promoting for
glioma cells in all. Recently, we had observed that delivering Fas-
Lribozyme into murine melanoma or Ras-activated NIH3T3 malig-
nant cell lines also effectively reduced apoptosis in those cells (our
unpublished data). It seems that the suicidal effect triggered by
Fas-L occur widely in many malignant cells. 
The proinflammatory effect of Fas-L has been recognized for
days and is attributed partly to local recruitment and activation of
neutrophils (Seino et al, 1997; Chen et al, 1998). Apoptotic body
by itself is a potent chemotactic agent for immune cells (Horino
et al, 1998). Besides, when phagocytes engulf apoptotic body, they
can effectively initiate T-cell immunity (Chattergoon et al, 2000).
Therefore, the Fas-Lribozyme-associated suppression in tumour-
infiltrating cells in nude mice observed in our system could be due
to reduced amount of apoptotic body generated by Fas-Lribozyme-
carrying cells. Alternatively, Fas/Fas-L engagement between
tumour and immune cells in subcutaneous environments will
trigger survival favouring signal for cells constituting innate
immunity as those cases reported for T cells or tumours (Alderson
et al, 1993, Owen-Shaub et al, 1994). This possibility waits to be
proven by additional study. It is noteworthy that U-373MG, 
U-118MG and their derivatives tested did not form large tumours
in nude mice. It substantiates the effectiveness of the remaining
innate immunity in nude mice for tumour control and partly
explains the negative correlation between cell infiltration and
tumour size in this study. Taken together, Fas-Lribozyme could
modify the tumorigenesis of human glioma cells in nude mice by
several ways. First, Fas-Lribozyme accelerated tumour cell growth by
improving cell viability. Second, Fas-Lribozyme reduced the innate
immune reaction against tumour. 
The appearance of glioma cells in the liver of tumour-bearing
mice was an unexpected finding. Even though tumour nodules
were not detected grossly in the liver, EGFP-expressing tumour
cells were detectable in this tissue. The glioma cells in liver lesion
were with atypical shape, mixed with apoptotic hepatocytes and
numerous inflammatory cells indicating rigorous local immune
responses. Growth of Fas-L+ tumour cells in syngeneic murine
host has been shown to induce toxicity in Fas+ organs probably
through the production of soluble Fas-L (Zeytum et al, 2000).
Hepatocytes are known to express Fas and are very sensitive to
Fas-L-mediated cytotoxicity (Ogasawara et al, 1993; Rensing-Ehl
et al, 1995). The expression of Fas-L in human colon cancer has
been correlated with the hepatic metastasis and the apoptosis of
hepatocytes in tumour lesion (Shiraki et al, 1997). In our study
model, Fas-Lribozyme reduced the severity of liver damage in
tumour-bearing mice. Therefore, the killing of hepatocytes in
glioma-bearing mice was obviously mediated by a contact with
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Figure 8 Apoptotic cells in tumour nodules. Apoptotic cells were detected
by Apop Tag-peroxidase in situ apoptosis detection kit. DNA strand break in
apoptotic cells was labelling and made visible as described in Material and
Methods. Apoptotic cells revealed brown colour. (A) EGFP(U-373MG); 
(B) Fas-Lribozyme(U-373MG); 400x 
Figure 7 Tumour-infiltrating cells. Tumour formation and cell staining were
done with same procedures as described in Figure 5. Arrowheads indicate
tumour-infiltrating cells. (A) EGFP(U-373MG); (B) Fas-Lribozyme(U-373MG);
400x 
A
Beither metastatic tumour cells or the infiltrating immune cells.
Overall, this work using a loss-of-function model appears to
complement previous Fas-L overexpression study and implies a
possible immune-stimulating function of Fas-L. 
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Figure 9 Liver lesions in mice bearing U-373MG-derived cells. Formalin-fixed, paraffin-embedded liver tissues were prepared from tumour-bearing mice. 
(A, B) haematoxylin/eosin-staining (40x). (A) EGFP(U-373MG); (B) Fas-Lribozyme(U-373MG). Arrowheads indicate some damaged tissue regions. 
(C) haematoxylin/eosin-staining of necrotizing area (400x), arrowheads marked some infiltrating immune cells. (D) Apoptotic cells were detected by 
ApopTag-peroxidase in situ apoptosis detection kit. Apoptotic hepatocytes (400x) are indicated by arrowheads. (E) EGFP-expressing cells (brown colour) in 
liver lesion (400x).(F) EGFP-expressing cells (brown colour) in tumour nodule (400x) 
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